Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16078179 | 0.92 | L3MBTL1 (0.46) | POLBL3MBTL1TSHRGAALMNA | |
| SCHEMBL21514117 | 0.90 | L3MBTL1 (0.53) | L3MBTL1TSHRGAALMNAALDH1A1 | |
| SCHEMBL20160108 | 0.90 | GAA (0.45) | POLBKDM5AL3MBTL1TSHRGAA | |
| SCHEMBL28944873 | 0.87 | POLB (0.61) | POLBKDM5AL3MBTL1TSHRGAA | |
| SCHEMBL13242299 | 0.86 | KDM5A (0.49) | POLBKDM5AL3MBTL1TSHRGAA | |
| SCHEMBL21037723 | 0.86 | KDM5A (0.49) | POLBKDM5AL3MBTL1TSHRGAA | |
| SCHEMBL1908725 | 0.86 | KDM5A (0.49) | POLBKDM5AL3MBTL1TSHRGAA | |
| SCHEMBL17756049 | 0.83 | POLB (0.45) | POLBL3MBTL1TSHRGAALMNA | |
| SCHEMBL21569624 | 0.82 | GAA (0.40) | POLBL3MBTL1TSHRGAALMNA | |
| SCHEMBL14820327 | 0.82 | POLB (0.41) | POLBKDM5AL3MBTL1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3581576-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| US-9820488-B2 | Compounds for the control of endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9820488-B2 | Compounds for the control of endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| US-9624241-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160251335-A1 | NEW COMPOUNDS | ELANCO TIERGESUNDHEIT AG (CH) | 2016-09-01 | — | — | US | disclosed |
| US-20160251335-A1 | NEW COMPOUNDS | ELANCO TIERGESUNDHEIT AG (CH) | 2016-09-01 | — | — | US | disclosed |
| US-9227985-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2015071417-A1 | New Compounds | NOVARTIS TIERGESUNDHEIT AG (CH) | 2015-05-21 | — | — | WO | disclosed |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251335-A1 | NEW COMPOUNDS | DDT, ACHE, PTMS | POLB 4688/4885KDM5A 1877/4885L3MBTL1 2166/4885 |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | POLB 1058/4885KDM5A 2823/4885L3MBTL1 697/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | POLB 194/4885KDM5A 470/4885L3MBTL1 1004/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | POLB 194/4885KDM5A 470/4885L3MBTL1 1004/4885 |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | POLB 1058/4885KDM5A 2823/4885L3MBTL1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.